Nightmares during Phenelzine Withdrawal

Joyce, Peter R.; Walshe, J. W. B.

doi:10.1097/00004714-198304000-00031

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 Withdrawal from tricyclic ADs may cause nightmares, 71,74,75,79 vivid dreaming 73 or "dream disturbance". 64 Also withdrawal of the monoamine oxidase inhibitors phenelzine 53,72,76,77 and tranylcypromine 69,70 may cause nightmares. The reviewed evidence on dream quality under SSRIs/SNRIs is less consistent, different effects are documented.…”

Section: Discussionmentioning

confidence: 99%

“…53 Five participants of case studies also reported nightmares during withdrawal of phenelzine. 72,76,77 In one of these cases disappearance of nightmares is documented 24 h after resumption of phenelzine therapy. 77…”

Section: Phenelzinementioning

confidence: 98%

“…80 However, out of seven other cases on fluoxetine, six participants reported clear nightmares, an intensification of dreaming in a negative way or both phenomena, 81,82,84,91 and one participant reported an emotionally undetermined intensification of dreaming. 83 Withdrawal of phenelzine resulted in nightmares in five participants 72,76,77 and in another participant in an emotionally undetermined intensification of dreaming. 72 Four depressive patients developed or perhaps unmasked RBD or RBD-like symptoms (intense dreams, themes of fighting, dream enacting, REM sleep without atonia documented in three 86,89,91 patients) apparently as a consequence of a newly established AD therapy.…”

Section: Clinical Findingsmentioning

confidence: 99%

“…markedly improved" without reporting a level of significance 53 ) was paralleled by a very high degree of dream suppression. 19,53 Withdrawal from phenelzine resulted in explicit nightmares 72,76,77 as well as in "frequently reported dreams, many of which were frightening" (statistically not tested). 53 …”

Section: Phenelzinementioning

confidence: 99%

See 3 more Smart Citations

Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers

Tribl

Wetter

Schredl

2013

Sleep Medicine Reviews

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Phenelzinementioning

confidence: 98%

Section: Clinical Findingsmentioning

confidence: 99%

Section: Phenelzinementioning

confidence: 99%

See 2 more Smart Citations

Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers

Tribl

Wetter

Schredl

2013

Sleep Medicine Reviews

View full text Add to dashboard Cite

“…Secondary nightmares may occur following administration of drugs such as L-dopa (Harsch, 1986), beta blockers (Besterman, 1983;Parkes, 1985), reserpine (Harsch, 1986;Parkes, 1985) and thiothixene (Solomon, 1983). They may also occur as a result of withdrawal from alcohol, amphetamines, hypnotics and phenalzine (Harsch, 1986;Joyce and Walshe, 1983). Nightmares are reported to occur with higher frequency among alcoholics (Cernovsky, 1985; and subjects with asthma (Klink and Quan, 1987).…”

Section: Aetiologymentioning

confidence: 99%

Dream Anxiety Disorders (Nightmares): A Review

Blanes

Burgess

Marks³

et al. 1993

Behav. Psychother.

View full text Add to dashboard Cite

Knowledge of the aetiology, epidemiology and treatment of nightmares has improved with more accurate definition of the problem. This review summarizes what is known about nightmares and their relationship with other medical and psychiatric disorders. Treatment methods are discussed, with particular reference to behavioural methods, which have become increasingly popular in recent years. Further research is suggested in order to determine the most efficient method of treating distressing nightmares.

show abstract

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract

Nightmares during Phenelzine Withdrawal

Cited by 7 publications

References 0 publications

Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers

Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers

Dream Anxiety Disorders (Nightmares): A Review

Monoaminergic‐based Pharmacotherapy for Depression

Contact Info

Product

Resources

About